<DOC>
	<DOCNO>NCT01672593</DOCNO>
	<brief_summary>Adjuvant use fibrin glue ( FG ) fistula tract show promote closure low-output ECFs . The primary objective study compare clinical efficacy , safety autologous platelet-rich fibrin glue ( PRFG ) commercially available fibrin sealant Bioseal® management patient low-output volume ECFs .</brief_summary>
	<brief_title>Glue Sealing Patients With Low-Output ECFs</brief_title>
	<detailed_description>- This prospective , randomize , single-centered study clinical , safety economic outcome ECFs patient . - Subjects randomized one 2 group : - Group 1 : Autologous PRFG-treatment ( PRFG + SOC ) - Group 2 : Commercial FG-treatment ( Bioseal® + SOC ) - Study include three phase : - Phase 1 : Screening , consent enrollment - Phase 2 : Patients receive either PRFG , Bioseal 14 day - Phase 3 : Follow : patient close fistula within 14 day , follow 6 month . For patient whose fistula still open treat therapeutic option follow 6 month closure .</detailed_description>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Digestive System Fistula</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Patients single tubular ECF Low output volume ( &lt; 200 ml/24h ) Tract length &gt; 2cm Tract diameter &lt; 1cm Cancerinfiltrated fistula Abscess Foreign body Distal bowel obstruction Inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Autologous platelet rich fibrin glue ;</keyword>
	<keyword>Enterocutaneous fistula ;</keyword>
	<keyword>Single low output GI fistula ;</keyword>
</DOC>